Search alternatives:
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
w decrease » we decrease (Expand Search), _ decrease (Expand Search), _ decreased (Expand Search)
50 ng » 50 mg (Expand Search), 10 ng (Expand Search), 5 ng (Expand Search)
5 w » 5 wt (Expand Search)
Showing 21 - 40 results of 65,408 for search '(( 5 ((mean decrease) OR (a decrease)) ) OR ((( 5 w decrease ) OR ( 50 ng decrease ))))', query time: 0.92s Refine Results
  1. 21
    Activating cAMP synthesis decreases liberation of propionyl-CoA from cholesterol.

    Activating cAMP synthesis decreases liberation of propionyl-CoA from cholesterol. by Kaley M. Wilburn (12060476)

    Published 2022
    Save to List
    Saved in:
  2. 22
    Frequency distribution of the hourly ERA5 reanalysis vs observations illustrating the best score (a: W02 station and b: W11 station) and the poorest score (c: W18 station and b: W19 station).

    Frequency distribution of the hourly ERA5 reanalysis vs observations illustrating the best score (a: W02 station and b: W11 station) and the poorest score (c: W18 station and b: W1... by Weidong Ji (129916)

    Published 2025
    Save to List
    Saved in:
  3. 23
    TREM1 inhibition decreases HIV mediated inflammatory cytokine production.

    TREM1 inhibition decreases HIV mediated inflammatory cytokine production. by Jinhee Hyun (6900683)

    Published 2019
    Save to List
    Saved in:
  4. 24
    S5 Fig -

    S5 Fig - by Jordan K. Abbott (8934239)

    Published 2022
    Save to List
    Saved in:
  5. 25
    The spectral sensitivity of European seabass fed a 5% taurine diet.

    The spectral sensitivity of European seabass fed a 5% taurine diet. by Richard W. Brill (2337940)

    Published 2019
    Save to List
    Saved in:
  6. 26
    MYCN overexpression leads to decreased <i>id2a</i> expression in early SCG.

    MYCN overexpression leads to decreased <i>id2a</i> expression in early SCG. by Rodrigo Ibarra-García-Padilla (19697623)

    Published 2024
    Save to List
    Saved in:
  7. 27
    TBEV-induced translational arrest results in the decreased protein levels of GAPDH, HPRT1, and viperin.

    TBEV-induced translational arrest results in the decreased protein levels of GAPDH, HPRT1, and viperin. by Martin Selinger (3195987)

    Published 2019
    Save to List
    Saved in:
  8. 28
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 29
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 30
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 31
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 32
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 33
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 34
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 35
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 36
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 37
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 38
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 39
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 40
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: